Leonard R. Duncan - Search Results

Year	Number of Results
2016	2
2017	4
2018	9
2019	5
2020	9
2021	5
2022	5
2023	2
2024	0

1

Screen for New Antimicrobial Natural Products from the NCI Program for Natural Product Discovery Prefractionated Extract Library.

Martínez-Fructuoso L, Arends SJR, Freire VF, Evans JR, DeVries S, Peyser BD, Akee RK, Thornburg CC, Kumar R, Ensel S, Morgan GM, McConachie GD, Veeder N, Duncan LR, Grkovic T, O'Keefe BR. Martínez-Fructuoso L, et al. Among authors: duncan lr. ACS Infect Dis. 2023 Jun 9;9(6):1245-1256. doi: 10.1021/acsinfecdis.3c00067. Epub 2023 May 10. ACS Infect Dis. 2023. PMID: 37163243 Free PMC article.

2

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii.

Michaeli J, Mandel S, Maximov S, Zazoun J, Savoia P, Kothari N, Valmont T, Ferrari L, Duncan LR, Hawser S, Cohen-Kutner M, Bachnoff N. Michaeli J, et al. Among authors: duncan lr. Antibiotics (Basel). 2022 Sep 5;11(9):1201. doi: 10.3390/antibiotics11091201. Antibiotics (Basel). 2022. PMID: 36139979 Free PMC article.

3

In Vitro Potency and Spectrum of the Novel Polymyxin MRX-8 Tested against Clinical Isolates of Gram-Negative Bacteria.

Duncan LR, Wang W, Sader HS. Duncan LR, et al. Antimicrob Agents Chemother. 2022 May 17;66(5):e0013922. doi: 10.1128/aac.00139-22. Epub 2022 Apr 27. Antimicrob Agents Chemother. 2022. PMID: 35475635 Free PMC article.

4

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).

Sader HS, Mendes RE, Duncan LR, Carvalhaes CG, Castanheria M. Sader HS, et al. Among authors: duncan lr. J Antimicrob Chemother. 2022 Sep 30;77(10):2642-2649. doi: 10.1093/jac/dkac233. J Antimicrob Chemother. 2022. PMID: 35897129

5

Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020.

Duncan LR, Hamed KA, Smart JI, Pfaller MA, Flamm RK, Mendes RE. Duncan LR, et al. Diagn Microbiol Infect Dis. 2022 Jul;103(3):115713. doi: 10.1016/j.diagmicrobio.2022.115713. Epub 2022 Apr 22. Diagn Microbiol Infect Dis. 2022. PMID: 35598410 Free article.

6

In vitro activity of iclaprim and comparator agents against Listeria monocytogenes clinical isolates from 2012 to 2018.

Huang DB, Duncan LR, Edah YK, Rhomberg PR, Flamm RK, Huband MD. Huang DB, et al. Among authors: duncan lr. J Glob Antimicrob Resist. 2021 Jun;25:14-17. doi: 10.1016/j.jgar.2021.02.015. Epub 2021 Mar 1. J Glob Antimicrob Resist. 2021. PMID: 33662644 Free article.

7

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020).

Sader HS, Castanheira M, Duncan LR, Mendes RE. Sader HS, et al. Among authors: duncan lr. Diagn Microbiol Infect Dis. 2023 Jan;105(1):115820. doi: 10.1016/j.diagmicrobio.2022.115820. Epub 2022 Sep 23. Diagn Microbiol Infect Dis. 2023. PMID: 36274343

8

Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe.

Sader HS, Carvalhaes CG, Duncan LR, Shortridge D. Sader HS, et al. Among authors: duncan lr. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00211-20. doi: 10.1128/AAC.00211-20. Print 2020 Apr 21. Antimicrob Agents Chemother. 2020. PMID: 32094135 Free PMC article.

9

Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA.

Lu Y, Vibhute S, Li L, Okumu A, Ratigan SC, Nolan S, Papa JL, Mann CA, English A, Chen A, Seffernick JT, Koci B, Duncan LR, Roth B, Cummings JE, Slayden RA, Lindert S, McElroy CA, Wozniak DJ, Yalowich J, Mitton-Fry MJ. Lu Y, et al. Among authors: duncan lr. J Med Chem. 2021 Oct 28;64(20):15214-15249. doi: 10.1021/acs.jmedchem.1c01250. Epub 2021 Oct 6. J Med Chem. 2021. PMID: 34614347

10

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients.

Sader HS, Duncan LR, Doyle TB, Castanheira M. Sader HS, et al. Among authors: duncan lr. JAC Antimicrob Resist. 2021 Sep 4;3(3):dlab126. doi: 10.1093/jacamr/dlab126. eCollection 2021 Sep. JAC Antimicrob Resist. 2021. PMID: 34514403 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

36 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year